The S1PR modulator Ozanimod reverses spine deficits, Amyloid-β plaques deposition and neuroinflammation in aged APP/PS1 mice
Rieke Fritz, Thomas Endres, Lukas Schoenwolf…·Volkmar Leßmann
This study shows that Ozanimod treatment reduces synaptic deficits, amyloid-β plaques, and neuroinflammation in aged APP/PS1 mice.